IMEDS Steering Committee Charge

The IMEDS Steering Committee will have a total of 12 members, comprised as follows:

1. FDA: 2 members (non-voting)
2. Pharmaceutical Industry: 3 members (at least 1 from small-medium sized company)
3. Academia / Research Institute: 2 members
4. Health System/Health Plan: 3 members (at least 1 from an integrated care system)
5. Patient/Consumer Advocacy Group: 2 members

Overview

A multi-stakeholder IMEDS Steering Committee (SC) will provide strategic guidance on the IMEDS program.

IMEDS Steering Committee Responsibilities

1. Provide strategic oversight to help to define overall program goals and to ensure the IMEDS program is achieving its objectives and producing high quality results.
2. Recommend opportunities to expand our partnerships and develop a collaborative model.
3. Identify potential risks and opportunities and advise the Foundation on ways to ensure the long-term sustainability of the program.
4. Recommend external communication strategies to further transparency of IMEDS activities and findings to the public.
5. Advise the Foundation on the IMEDS governance structure, i.e., ad hoc project committees.
6. Evaluate any conflict of interest issues escalated by the IMEDS Program Team and recommend management plans as appropriate.
7. Adjudicate disagreements among the study team should they arise or appoint an ad hoc group of experts to do so.
8. Nominate IMEDS Steering Committee members to replace departing members (subject to RUF Board approval).
9. Attend monthly conference calls and at least one in-person meeting in Washington, DC per year.

Tenure

All Committee appointments will be generally 36 months. Some exceptions may apply.